Consensus Shanghai Henlius Biotech, Inc. OTC Markets

Equities

Market Closed - OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

05-14	Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	MT
05-14	Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration	CI

4f90a040d6c.KiF-qPxtqfCA5MiauooUz4886YZB1SagdKwHxrv60X0.R34Y7L9bnrLUi5usiLJWuexVrugAkV7wHoFMs--flzobDAT-pi-Ens-hgQ~de017a13b66f9170050cafcfd961efba

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.28 CNY

Average target price

16.7 CNY

Spread / Average Target

+2.62%

High Price Target

23.05 CNY

Spread / Highest target

+41.62%

Low Price Target

8.352 CNY

Spread / Lowest Target

-48.68%

Trading Rating

Investor Rating

ESG Refinitiv